---
title: "Zepp Health soars 17% during regular trading"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305475139.md"
description: "Zepp Health rose 17.13% to US$2.940. Up 30.67% over five sessions and down 89.09% YTD."
datetime: "2026-11-13T20:20:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305475139.md)
  - [en](https://longbridge.com/en/news/305475139.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305475139.md)
generator: "portal-rs"
---

# Zepp Health soars 17% during regular trading

Zepp Health (ZEPP.US) soared more than **17%** during regular trading to **$2.94**.

The stock is up 30.67% over the past five sessions and down 89.09% year to date. It sits 36.74% above its 52-week low of US$2.150. Volume was 3.10 times its average and the intraday swing reached 12.35%.

The Nasdaq Composite is up 2.21% over the past five sessions and up 8.09% year to date.

Based on public media reports. AI-generated; not investment advice.

### Related Stocks

- [ZEPP.US](https://longbridge.com/en/quote/ZEPP.US.md)

## Related News & Research

- [Zepp Health Non-GAAP EPADS of -$0.79, revenue of $63.53M; gives Q3 outlook](https://longbridge.com/en/news/297733174.md)
- [Space Exploration Technologies (SPCX) Gets A New Hiring Twist As Musk Eyes Top AI Talent](https://longbridge.com/en/news/306383945.md)
- [Nasdaq (NDAQ) Just Gave Investors Something To Think About](https://longbridge.com/en/news/306370324.md)
- [Anthropic PBC (ANT) Claims Claude Solved The 167 Year Old Riemann Hypothesis](https://longbridge.com/en/news/306374461.md)
- [CAPR: FDA issued a CRL for Deramiocel, citing insufficient evidence of effectiveness](https://longbridge.com/en/news/306366333.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**